Beacon Therapeutics' laru-zova meets FDA-endorsed VISTA Phase II/III endpoint

Reuters' timestamped report provides explicit new information: Beacon Therapeutics said laru-zova met the FDA-endorsed primary endpoint in the Phase II/III VISTA trial with statistically significant low-luminance visual acuity (LLVA), and outlined pre-submission discussions plus a rolling U.S. BLA plan. This is a forward-looking clinical catalyst, so it is approved and typed as clinical_study; the regulatory activities are plans, not approvals. Importance is set at 0.82 because the pivotal readout could materially affect regulatory and commercial expectations, while surprise is 0.60 because no market-consensus baseline is provided. Confidence is 0.92 based on direct source support, with lower timestamp confidence because the source provides a report timestamp rather than a separately stated event time. MGTX is the only approved stakeholder because it has a clearly evidenced competing XLRP program; the supplier, payer, broader modality, and other read-throughs are too indirect or insufficiently specific for approval.